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Intervention into amyloid deposition with anti-amyloid
agents like the polyphenol epigallocatechin-3-gallate (EGCG) is
emerging as an experimental secondary treatment strategy in
systemic light chain amyloidosis (AL). In both AL and multiple
myeloma (MM), soluble immunoglobulin light chains (LC) are
produced by clonal plasma cells, but only in AL do they form
amyloiddeposits in vivo.We investigated the amyloid formation
of patient-derived LC and their susceptibility to EGCG in vitro
to probe commonalities and systematic differences in their
assemblymechanisms.We isolatednineLC fromtheurineofAL
and MM patients. We quantified their thermodynamic stabili-
ties and monitored their aggregation under physiological con-
ditions by thioflavin T fluorescence, light scattering, SDS stabil-
ity, and atomic force microscopy. LC from all patients formed
amyloid-like aggregates, albeit with individually different kinet-
ics. LC existed as dimers, 50% of which were linked by disul-
fide bridges. Our results suggest that cleavage into LC mono-
mers is required for efficient amyloid formation. The kinetics of
AL LC displayed a transition point in concentration depen-
dence, which MM LC lacked. The lack of concentration depen-
dence of MM LC aggregation kinetics suggests that conforma-
tional change of the light chain is rate-limiting for these
proteins. Aggregation kinetics displayed two distinct phases,
which corresponded to the formation of oligomers and amyloid
fibrils, respectively. EGCG specifically inhibited the second
aggregation phase and induced the formation of SDS-stable,
non-amyloid LC aggregates. Our data suggest that EGCG inter-
vention does not depend on the individual LC sequence and
is similar to the mechanism observed for amyloid- and
-synuclein.
Systemic light chain amyloidosis (AL)2 is the most common
formof systemic amyloidosis (1), but it is still a rare diseasewith
an incidence of 6–7 in 1,000,000 people (2). Underlying AL
pathology is a clonal plasma cell disorder, which produces an
immunoglobulin light chain in the bone marrow with a unique
sequence. These light chains are released into the blood (mono-
clonal gammopathy). When elevated LC levels in serum over-
whelm renal absorption, LC is also found in the urine. Full-
length LC can be isolated from the urine of these patients (3–5).
Clonal plasma cell disorders can present different types of
pathologies; light chains form amyloid deposits in AL patients.
Here, LC fibrils adopt a conformation characterized by highly
stable, intramolecular cross--sheets that stain with Congo red
(6) and thioflavin T (ThT) (7–9).
In contrast, amyloid deposits are not observed in patients
suffering from multiple myeloma (MM), a malignant disease
characterized by bone marrow failure and bone destruction.
The two contrasting pathologies of LC gammopathies raise the
question of which factors determine amyloid formation. Amy-
loid formation could be initiated (a) by the sequences of the
individual light chains, (b) by high levels of light chain expres-
sion, (c) by posttranslationalmodification of the LC, (d) by frag-
mentation of the light chain, or (e) by a combination of these
factors. A possible modification would be the formation or
cleavage of intermolecular intradomain disulfide bonds.
The variable (VL) and constant (CL) domains of LC proteins
are connected by a short joining domain (10–13). Both contain
an intradomain disulfide bridge (10–15) between Cys-23 and
Cys-104. Additionally, the constant domain can form inter-
chain disulfide bonds to Ig heavy or light chains (10–13) via its
conserved Cys-127 residue (16, 17).
Previous quantitative studies have focused on a small num-
ber of recombinant proteins spanning the variable domain of
the LC proteins (18–26). These systems cannot address the
relevance of interdomain interactions in LCamyloid formation.
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The significance of full-length LC for amyloid formation is not
yet fully understood (27–30).
Our study, for the first time, quantifies stabilities and amy-
loid formation propensities of nine authentic, full-length LC
proteins that we isolated from the urine of patients (4 with AL,
5withMM).Our study testedwhether AL andMM light chains
had inherently different stabilities or amyloid formation pro-
pensities. We found that both AL and MM full-length light
chains formed amyloid aggregates in vitro, but only under
conditions that cleaved intermolecular disulfide bonds.
Aggregation kinetics were unique for each LC protein and
correlated only weakly with thermodynamic stability.
Treatment for the plasma cell clone pathology exists in the
form of chemotherapy, but the direct treatment of amyloid
pathology is still under investigation. Recently, we could show
that the green tea polyphenol epigallocatechin-3-gallate
(EGCG) redirects amyloid formation of amyloid- and -sy-
nuclein into inert amorphous aggregates (31–33). A case report
of a patient who self-administered EGCG after several cycles of
chemotherapy found that EGCG reduced LC deposits in the
patient’s heart and extended the patient’s life over a period of
several years (34). A reduction in cardiac pathology was
observed in some but not all patients treated with EGCG (35).
This observation raises the possibility that LC proteins from
different patients may respond differently to EGCG.
Our study therefore tested the effect of EGCG on amyloid
formation kinetics of our nine patient-derived LC proteins.We
found that EGCG inhibited the conversion of oligomeric LC
into ThT-positive fibrils and induced the formation of SDS-
stable aggregates in all LC proteins.
Results
Purification of Ig Light Chains from Patient Urine—Utilizing
a simple protocol, we purified nine monoclonal Ig light chains
from the urine of patients. Patients displayed either MM
pathology or AL pathology. AL patients also displayed MM
markers in addition to AL pathology (AL  MM in Table 1).
Instead of a standard dialysis approach (27, 36, 37), we utilized
sequential membrane ultrafiltration, which removed small
molecule components and concentrated the LC by a factor of
40–80 (Fig. 1A) (38). This protocol allowed us to parallelize the
purification of a larger set of patient samples efficiently.
LC samples were analyzed via denaturing (DTT, heating to
95 °C, 2% lithium dodecyl sulfate (LDS)) and semidenaturing
(no DTT, no heat, 2% LDS) SDS-PAGE (Fig. 1B). Each protein
was analyzed by silver staining, showing the total protein
amount (Fig. 1B, lane t), and byWestern blotting against -iso-
type LC (Fig. 1B, lane ), -isotype LC (Fig. 1B, lane ), and
human serum albumin (Fig. 1B, lane a), respectively.
Purified LC selected for further biochemical and biophysical
analysis contained less than 6% albumin and came from
patients with a minimum of 265 mg of LC/24 h of secretion in
urine (Table 1). These samples showed at most a weak 67 kDa
band in silver staining (Fig. 1B, lane t) that was confirmed as
albumin by immunostaining (Fig. 1B, lane a).
The isolated LC proteins each were of a single isotype that
ran in SDS-PAGE as single bands with apparent molecular
masses of 24–28 kDa. Under non-reducing conditions, both
monomers and S-S-linked dimers were present. Densitometric
analysis of silver-stained proteins found 46 11%of LCdimers.
However, analysis by blue native PAGE (Figs. 4B and 5A), size
exclusion chromatography, and dynamic light scattering (data
not shown) revealed that the light chain proteins did not, in fact,
present as free monomer and dimers, as suggested by SDS-
PAGE analysis. Rather, LC ran as distinct di- and oligomeric
species between 50 and 600 kDa, suggesting the formation of
non-SDS-stable multimers built from LC monomers and
dimers. Purification of LC by an alternative dialysis protocol
yielded di- and oligomers identical to those yielded by our
membrane filtration protocol (Fig. 1C). These data confirm that
oligomeric LC species were present in the patient urine and not
a result of our purification protocol. Strikingly, light chains
largely ran as monomers in native PAGE after reduction with
DTT (100 mM; Fig. 1D), suggesting that reduction of intermo-
lecular disulfide bonds destabilized LC oligomers.
Secondary Structure and Thermal Stability of Light Chains—
When analyzed by CD spectroscopy, LC proteins exhibited the
expected-sheet structure (Fig. 2,A andB) (39, 40). CD spectra
could be grouped into - (Fig. 2A) and -isotype (Fig. 2B) LC
(41). However, we observed no systematic differences between
samples coming fromMM or AL patients.
We then tested whether the stability of LC correlated with
MMorALpathology by recording thermal denaturation curves
of the nine LC proteins (Fig. 2, C and D). Results are summa-
rized in Table 2. Similar to the CD spectra, the melting points
(Tm) grouped according to the LC isotypes (Table 1; -LCTm
48.6–51.6 °C, -LC Tm  55.3–61.5 °C) with the exception of
TABLE 1
Summary of clinical data for AL andMM patients
IFE, immunofixation electrophoresis; NA, not applicable; GI, gastrointestinal.
Sample ID Patient ID
Age (years)/
Gender Type
IFE Protein serum Protein urine Involved
organsSerum Urine    
mg/liter mg/liter
-AL-1 35-12 59/femal ALMM   11,300 8 5,460 0 Soft tissue,
GI tract
-AL-2 48-12 55/male ALMM IgG   3,750 1 4,242 6 Soft tissue
-AL-1 95-12 54/female ALMM   12 6,470 22 5,784 Soft tissue
-AL-2 66-12 66/male ALMM   6 654 0 265 Soft tissue,
GI tract
-MM-1 344-13 64/male MM IgG   2,173 5 3,400 0 NA
-MM-2 369-13 50/female MM   33,209 1 2,437 3 NA
-MM-1 85-12 60/male MM IgA   0 5,780 0 17,368 NA
-MM-2 448-13 47/female MM IgA  IgA,  0 1,495 0 9,016 NA
-MM-3 44-13 60/male MM   18 2,050 36 2,100 NA
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the -MM-1 (Tm  60.4 °C, light green), which had a higher
thermal stability than other -LC. These data suggest that the
- and -isotypes of constant domains have a stronger influ-
ence on the overall LC stability than the individual variable
domains (42). Reduction of LC with DTT under native condi-
tions had little effect on stability (Fig. 2E). In contrast, reduction
under denaturing conditions reduced thermal stability by
12 °C (Fig. 2E). These results are consistent with literature
data comparing the effect of inter- versus intramolecular disul-
fide bonds on LC stability (43). The results also indicate that
only intermolecular disulfide bonds were reduced under the
conditions of our aggregation assay.
We observed a temperature gradient-dependent hysteresis
of 2.6–7.7 °C between denaturation and renaturation curves
(data not shown). This behavior has been described for recom-
binant VL domains and full-length LC (44). Although no obvi-
ous differences in thermal stability between AL and MM LC
were observed during denaturation, -MM proteins did not
renature into their native fold. These LC irreversibly formed
aggregates after prolonged denaturation (not shown). Denatur-
ation of all other LC proteins was at least partially (45–80%)
reversible. This difference may reflect a difference in unfolding
and aggregation pathways between light chains in AL andMM
patients.
Thermodynamic Stabilities of Light Chains—We determined
the free energies of unfolding via guanidine hydrochloride
(GdnHCl) denaturation and monitored unfolding via trypto-
phan fluorescence (14, 15, 45–48) (Fig. 3A). The VL and CL
domains contain a conserved tryptophan in position 41, the
-isotype CL domain contains an additional conserved Trp-96,
and 0–4 non-conserved Trp residues may be present (16, 17).
Fluorescence spectra exhibited both changes in intensity and
shifts of the emission maximum on unfolding (Fig. 3, A and B).
We incubated all samples at 6 M GdnHCl overnight and then
FIGURE 1.A, purification of Ig light chains fromurine of patients diagnosedwith AL orMM. B, denaturing and semidenaturing SDS-PAGEwith silver staining for
total protein (t) and Western blotting analysis for -LC (), -LC (), and human serum albumin (a). C, native PAGE Western blotting of -AL light chain urine
sample purified by two alternative protocols, membrane filtration or dialysis. Both purification protocols yielded identical patterns of di- and oligomeric LC.D,
Coomassie-stained native PAGE of light chain samples. LC (100M)were treatedwith DTT (100mM) for 30min in NaP buffer, diluted to 40M, and analyzed by
blue native PAGE. Reduction removed HMW oligomers.
LC Aggregation and EGCG
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diluted the sample to 0.025 M GdnHCl to test for reversibility
of unfolding (supplemental Fig. 1). CD spectra indicated that
LC refolded into a native-like conformation (Table 2 and sup-
plemental Fig. 1).
We analyzed denaturation and renaturation data for the
-AL-1 light chain recorded by Trp fluorescence and by CD
spectroscopy in more detail (Fig. 3, C and D). Unfolding ener-
gies (10  1 kJ/mol) and refolding energies (11  5 kJ/mol)
measured by fluorescence and by CD (13  5 kJ/mol) were
identical within experimental error. This indicated that unfold-
ingwas fully reversible and could bemeasured by bothmethods
with similar accuracy.
We then analyzed unfolding data of our nine light chains
(Fig. 3, E and F); all denaturation data are summarized in Table
2. -MM light chains were slightly more stable (13 1 kJ/mol,
and 14  1 kJ/mol) than the -AL samples (9  1 and 10  1
kJ/mol). Similarly, -MM light chains (-MM-1, 17 2 kJ/mol;
-MM-2, 14  1 kJ/mol; and -MM-3, 16  5 kJ/mol) were
FIGURE 2. A and B, CD spectra of purified -isotype and -isotype LC. C and D, thermal denaturation curves (heating rate 0.5 °C/min); apparent melting points
(Tm) for -LC of 48.6–51.6 °C (-MM-1, Tm 60.4 °C) and for -LC of 55.3–61.5 °C; see Table 2 for detailed data. E, thermal denaturation of -AL-1 LCmeasured
without denaturation (native, Tm 46 0.5 °C), after reduction of the intermolecular disulfide bonds under native conditions (DTT, Tm 43 1 °C), or after
reduction of inter- and intramolecular disulfide bonds in the GdnHCl denatured state (denat DTT, Tm 31 0.5 °C).
TABLE 2
Summary of thermodynamic parameters and apparent molecular weights of Ig light chain proteins
NA, not applicable; ND, not determined; Max., maximum.
Sample
GdnHCl denaturation Thermal denaturation SDS-PAGE
% final HSAa Refoldingb cm unfoldingc G0 unfolding G0 refolding
Max. Trp fluorescence
Refoldingb Tm(app)d Apparent masseBefore After
% % M kJ kJ nm % °C kDa
-AL-1 0.3 100 1.0 0.05 9 1 ND 350 71 48.6 0.2 24
-AL-2 3.6 100 2.2 0.05 10 1 ND 344 349 50 51.6 0.1 26
-AL-1 5.8 100 1.2 0.05 10 1 11 5 338 350 87 58.3 0.1 26
-Al-2 2.2 92 1.9 0.05 14 3 ND 331 349 59 55.3 0.1 28
-MM-1 0.8 100 1.5 0.05 14 1 ND 350 75 60.4 0.1 25
-MM-2 2.1 100 1.3 0.05 13 1 ND 346 349 66 50.5 0.1 26
-MM-1 0.4 84 1.3 0.05 17 2 NA 320f 349 3 59.3 0.1 27
-MM-2 3.5 78 1.6 0.05 14 1 NA 326f 348 7 60.2 0.1 27
-MM-3 4.3 83 1.6 0.05 16 5 NA 325f 350 7 61.5 0.1 28
a Final HSA determined in purified sample.
b Determined from CD data.
c Denaturant concentration at 50% unfolding.
d Apparent melting temperature determined with a heating rate of 0.5 K/min.
e Apparent molecular mass determined from reducing SDS-PAGE.
f For these samples, no distinct pre-transition peak position was found, and the Trp fluorescence intensity ratio at the indicated wavelengths was analyzed instead.
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more stable than -AL light chains (-AL-1, 10  1 kJ/mol;
-MM-2, 14  3 kJ/mol). In summary, MM light chains were
marginally more stable than the AL light chains.
Aggregation of Light Chains—LC proteins are deposited in
AL patients into amyloid aggregates, which can be stained by
amyloidophilic dyes, such as Congo red andThT.We chose the
-AL-1 light chain to establish conditions for amyloid forma-
tion in vitro.
We determined the sequence of the -AL-1 LC by MS pep-
tide mapping combined with de novoMS sequencing (49). We
found 10 point mutations compared with the parent germ line
sequence (IGLV1-44*01; IGLC-3*03) (Fig. 4A). All mutations
are in the VL domain. Four mutations are concentrated in
CDR3 (complementarity-determining region 3).We analyzed
the amyloidogenicity of the -AL-1 LC using theWALTZ algo-
rithm (50). WALTZ predicted two amyloidogenic regions in
theVLdomain of the germ line parent at aa 32–38 and aa 45–51,
respectively. Interestingly, mutations S36G and Q44H of the
-AL-1 light chain flank the first amyloidogenic region. Sur-
prisingly, mutations I54M and N65D in -AL-1 removed the
amyloidogenicity in the second region. The analysis suggests
that the relation between point mutations in clonal LC and
amyloid formation is complex. The accumulation of amyloid-
promotingmutations is probably not the only factor that deter-
mines amyloid formation in vivo.
We incubated -AL-1 LC for 1 day under permanent shaking
in 25 mM sodium phosphate (pH 7.2), 120 mM NaCl at 37 °C.
The light chain remained soluble under non-reducing condi-
tions. In contrast, it formed large aggregates when incubated
under reducing conditions (8 mM DTT). In native PAGE, we
observed LC aggregates (720 kDa) and highmolecular weight
(HMW) aggregates incapable of migrating into the gel after 1
FIGURE 3.GdnHCl denaturation data. A, absolute intensity Trp fluorescence spectra of -AL-1 light chain. B, Trp fluorescence spectra of -AL-1 normalized to
fluorescencemaximum.C, unfolding (blue) and refolding (light green) curves as a function of GdnHCl concentration analyzed from the ratio of Trp fluorescence
intensities at 339 and 350 nm, respectively.D, comparison of unfolding curves from fluorometric (dark blue) andCD spectroscopic data (red). E and F, unfolding
curves of all -LC (E) and all -LC (F). Curves for -LC and -AL-2 are derived from Trp fluorescence data; other -LC curves are derived from CD signals at 211
nm. Data points represent means S.D. from three independent experiments.
LC Aggregation and EGCG
2332 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 6•FEBRUARY 10, 2017
 at M
ax-D
elbrück-Centrum
 für M
olekulare M
edizin on A
ugust 24, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
day of incubation (Fig. 4B). AFM imaging confirmed that large
aggregates were formed in the presence of DTT, whereas in
the absence of DTT, no aggregates were visible (Fig. 4C). The
-AL-1 LC formed a mixture of amorphous and fibril-like
structures at neutral pH (Fig. 4C). These aggregates bound the
amyloidophilic dyes ThT and Congo red and displayed Congo
red fluorescence and birefringence (Fig. 4, D and E). Aggrega-
tion kinetics followed a sigmoidal time course that is typical for
amyloid formation (Fig. 4E). We analyzed the aggregation of all
nine LC under the same conditions. AL LC formed aggregates
with fibrillar substructure at neutral pH, whereas aggregate
morphologies of MM LC were diverse. All light chains formed
typical amyloid fibrils when incubated at pH 2.8 (Fig. 4C and
supplemental Fig. 2), displayed SDS resistance (Fig. 5), and
bound ThT (Fig. 6). Hence, light chains isolated from patients’
urine formed aggregates with amyloid characteristics under
reducing conditions.
Characterization of Light Chain Aggregates by Native PAGE
and SDS-PAGE—Resistance to denaturation by SDS is a char-
acteristic property of amyloid. We monitored aggregation of
light chains over 3 weeks to test whether aggregates would
acquire resistance to denaturation in SDS. Samples were frozen
after 0, 0.2, 1, 2, 5, 7, 14, and 21 days and stored at 80 °C for
further analysis. All nine LC proteins formed large aggregates
within 1 daywhen analyzed by native PAGE (Fig. 5A). However,
at this time point, LC aggregates were still disaggregated into
monomers by 2% LDS at room temperature (semidenaturing
conditions). Light chains formed aggregates that were resistant
to denaturation at room temperature within 5–7 days (Fig. 5B).
All nine LC samples displayed similar aggregation kinetics,
althoughMMlight chains rapidly formed very large SDS-resist-
ant aggregates that did not enter the gel. In contrast, LC from
AL patients produced aggregates that ran as dimers or oligo-
mers (Fig. 5B), whichmay reflect differences in the aggregation
mechanism.
To analyze differences in aggregate stability, we denatured
LC samples by boiling in 2% LDS after a 21-day incubation.
Under these denaturing conditions, LC aggregates dissociated
into discrete ladders of monomeric, dimeric, and higher multi-
meric species (Figs. 5C (top) and 8). However, a substantial
fraction of MM LC remained in the form of HMW aggregates
that did not enter the gel. We then performed an ultracentrif-
ugation experiment for 30 min at 200,000  g to test whether
SDS-resistant oligomers were the result of a disaggregation of
FIGURE 4. Ig light chain-AL-1 aggregated under reducing conditions. A, two-layer Collier de Perles representation of the -AL-1 sequence. Squares, limits
of complementarity-determining regions. Amino acids with red letters indicate highly conserved position. Mutations from the germ line parent domain are
markedwith orange circles, and the parent amino acid is shown beside eachmutation. B, native PAGE shows formation of large (720 kDa) and highmolecular
weight aggregates incapable of migrating into gel (arrows) after incubation of LC (20 M) for 1 day at 37 °C, in NaP2 buffer containing DTT (8 mM). C, AFM
imaging of LC aggregates after 1- and 21-day incubation under neutral or acidic conditions. D, -AL-1 light chain aggregated for 1 week, stained with Congo
red, and imaged by fluorescence (1), birefringence (2), and overlay (3). E, ThT-positive aggregates formed only in the presence of DTT (100 mM).
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larger aggregates. Supernatants and washed pellets were dena-
tured by boiling in 2% LDS and analyzed by denaturing SDS-
PAGE (Fig. 5C). All LC protein was pelleted by ultracentrifuga-
tion, and no oligomers were visible in the supernatant fraction.
This indicates that oligomeric species in SDS-PAGE resulted
from partial denaturation of high molecular weight aggregates
(Fig. 5C).
Aggregation Kinetics of Light Chains—We recorded aggrega-
tion kinetics of light chains by ThT fluorescence and by light
scattering. Ig light chains formed ThT-positive aggregates at
neutral pH under reducing conditions, which could be also
observed turbidimetrically (Fig. 6A). We observed two types of
aggregation kinetics that are represented by the four light
chains shown in Fig. 6A. In most light chains, ThT aggregation
kinetics showed a biphasic behavior with a very rapid initial rise
inThT fluorescence, as exemplified by LC-AL-1 and-MM-1
(Fig. 6, A and B, and supplemental Fig. 3, A and B). This rapid
first phase of aggregation was invisible to turbidity measure-
ments. This suggests that it corresponded to the formation of
small oligomeric species (Fig. 6A). In contrast, the second
phase, which was observable in both ThT and light scattering,
corresponded to the formation of larger aggregates. However,
the relativeThT fluorescence amplitudes of the first and second
aggregation phases varied. Light chains -AL-1 and -MM-1
lacked detectable first aggregation phases.
We tested whether human serum albumin (HSA) had any
influence on ThT kinetics of LC proteins by supplementing
-AL-1 LC aggregation assays with HSA (supplemental Fig. 3
C). We found no effect of albumin on the first aggregation
phase and a weak delay of the second aggregation phase at 10%
of the LC concentration. This albumin concentration was
higher than the HSA present in any of our purified LC samples.
Therefore, we conclude that albumin had little or no effect on
the LC aggregation kinetics under the conditions of our assay.
We could fit aggregation data to two sigmoid growth terms
that corresponded to fast oligomer formation and to slower
FIGURE 5. A, native PAGE of LC aggregated for 1 day. LC proteins formed large aggregates (720 kDa) and HMW aggregates that were unable tomigrate into
gels. AL light chains producedmainly large aggregates, andMM samples producedmainly HMWaggregates. B, semi-native SDS-PAGE (no DTT, no heat) of LC
aggregates formed in long term aggregation assays for 21 days. C, ultracentrifugation experiment of 21-day aggregates observed via denaturing SDS-PAGE
(DTT, heating to 95 °C). Aggregates from all LC samples dissociated into distinct ladder-like monomeric, dimeric, and multimeric species and residual HMW
aggregates (top). These species are not soluble protein (middle) but insoluble aggregates sensitive to denaturing conditions (bottom).
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fibril formation (Fig. 6B).We performed concentration-depen-
dent aggregation assays between 5 and 100 M initial LC con-
centration (Fig. 6B and supplemental Fig. 3A) and determined
time constants for both phases of the aggregation kinetics (Fig.
6C and supplemental Fig. 3B). The second phase of aggregation
kinetics depended on protein concentration, whereas the first
phase was largely independent of LC concentration. This sug-
gests that a structural transition rather than an assembly step
was rate-limiting in the first phase of the aggregation kinetics.
We found that the first phase of aggregation accelerated with
increasing concentration ofDTT (supplemental Fig. 3D). These
data strongly suggest that oligomer formation was initiated by
the reduction of disulfide bonds.
Weplotted the time constants (t50) of the second aggregation
step logarithmically as a function of LC concentration to ana-
lyze the underlying aggregation mechanism (51). All proteins
displayed very weak concentration dependences with slopesm
between0.15 and0.25 at low protein concentrations. Strik-
ingly, concentration dependence of MM LC was weak (m 	
0.2) in the whole concentration range probed in our experi-
ment. In contrast, the concentration dependence of most AL
LC curved from a flat slope at low concentrations to a slope of
0.5 at higher protein concentrations.
Concentration dependences at low LC concentrations are
much smaller than what would be predicted for a nucleated
polymerizationmechanism, for which the concentration depend-
ence of ln t50 scales with the nucleus size n asm(n 1)/2
(52). A slope of m  0.5 is expected for aggregation that is
dominated by secondary nucleation or by prion-like replication
of amyloid fibrils (51). Therefore, our data suggest that fibril
formation is dominated by unimolecular processes at low LC
concentrations. A plausible explanationwould be that a confor-
mational conversion step of the LC limits the formation of amy-
loid fibrils. However, the aggregation of AL LC at higher con-
centration is dominated by protein assembly. Our data would
be compatible with a mechanism that is limited by dimer for-
mation or dominated by secondary processes (51). In contrast,
conformational change remained dominant in MM LC under
FIGURE 6. A, aggregation kinetics measured by ThT fluorescence and turbidity (560 nm) of selected LC samples. B, ThT aggregation kinetics at different LC
protein concentrations. Samples showbiphasic aggregation kinetics that were fittedwith two Boltzmann growth terms (red). C, concentration dependence of
the second Boltzmann time constant (t2) for all LC samples plotted on a logarithmic scale.
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all conditions. Therefore, our kinetic data suggest that the dif-
ference in LC from patients with an AL diagnosis and those
from MM patients may lie in the ease with which the LC con-
verts into an amyloid-competent conformation.
The Effect of Epigallocatechin-3-gallate on Light Chain Ag-
gregation—Having established the aggregation characteristics
of our light chain proteins, we then analyzed the influence of
EGCG on aggregate formation. We incubated Ig light chains
under the same conditions as before in presence of equimolar
(1) or 5-fold excess (5) of EGCG (Fig. 7, A and B). In all
cases, EGCGcompletely prevented the second aggregation step
but did not affect the first step in ThT kinetics (Fig. 7, A and B,
and supplemental Fig. 4A). Correspondingly, the addition of
EGCG to the LC sample after the first aggregation step (t 4 h)
had the same effect on ThT fluorescence as the addition at t
0 h (supplemental Fig. 4B).
AFM imaging showed that EGCG did not prevent aggregate
formation. LC formed aggregates of variedmorphologies in the
presence of EGCG (supplemental Fig. 2). We therefore tested
whether EGCG had changed aggregate stabilities. We and oth-
ers had previously observed that EGCG can induce the forma-
tion of SDS-stable aggregates of other amyloidogenic proteins
(31, 53–56). HMW aggregates formed in the absence of EGCG
were broken down by boiling in LDS (Fig. 8). Although EGCG
had little effect on LC aggregate sizes analyzed by native and
semidenaturing PAGE (data not shown), it induced the forma-
tion of SDS-stable aggregates (Fig. 8). These SDS-stable aggre-
gates increased in size with prolonged incubation times,
whereas LC aggregates remained labile to denaturation in the
absence of EGCG.
The data from SDS-PAGE suggest that EGCG induced the
formation of insoluble, SDS-resistant aggregates. We tested by
ultracentrifugation whether LC treated with EGCG did indeed
become insoluble. Aggregates formed in the presence of EGCG
after 21 days of incubation were pelleted by ultracentrifugation
and analyzed by denaturing SDS-PAGE (Fig. 9). As expected,
the aggregates formed in the presence of EGCG were insoluble
and pelleted nearly completely.
Therefore, we conclude that EGCG had a similar effect on all
nine examined light chains independently of the LC isotype and
sequence and the originating disease. EGCG did not prevent
the aggregation of the light chains. Rather, it induced their
aggregation into SDS-resistant structures. While doing so,
EGCG did not fundamentally alter aggregation kinetics of the
nine LC relative to each other. LC proteins that rapidly formed
HMW aggregates also more rapidly formed SDS-stable aggre-
gates in the presence of EGCG and vice versa.
Discussion
Inhibition of amyloid deposition is emerging as a potential
secondary treatment option in AL amyloidosis. Compounds
like EGCG can inhibit amyloid formation in a wide variety of
misfolded proteins in vitro and in animal models (57). Prelimi-
nary evidence suggests that EGCG may counteract amyloid
deposition in AL patients and improve their prognosis (34, 35,
58). However, the fact that light chains are uniquely different
from patient to patient poses specific challenges to the study
and to the treatment of AL amyloid deposition.
A number of studies have scrutinized the factors governing
LC amyloid formation, most of which have been performed on
recombinant variable domains from five different LC proteins:
Wil and Jto (18, 19), AL-09 and AL-103 (20–24), and SMA (25,
26). Studies on VL domains (18, 59–61) found that their amy-
loidogenicity roughly correlatedwith their thermodynamic sta-
bility. More recent studies have painted a more differentiated
picture.Mutations that alter the interface inAL-LCdimersmay
FIGURE 7. A, ThT kinetics in the absence (0) of EGCG, with equimolar (1) and 5-fold molar excess of EGCG (5) in relation to LC concentration. EGCG
prevented formation of ThT-positive species in the second aggregation phase. B, magnification of the first 2.5 days of aggregation.
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alter amyloid formation without altering VL monomer stability
(44, 62).
We have generated detailed sequence information for one of
our LC proteins (-AL-1) and found 10 substitutions from the
germ line parent in the VL domain but no mutations in the CL
domain. Half of the point mutations in this protein affected
regions that are predicted to be amyloidogenic. Interestingly,
thesemutations did not uniformly increase amyloid propensity.
Rather, two mutations flanked region 1 (aa 37–43), and two
others strongly reduced the amyloid propensity of region 2 (aa
45–51). At the same time, we have no evidence that the muta-
tions lowered the thermodynamic stability of the LC, because
stabilities of all -LC were very similar to each other (Fig. 3F).
This finding supports the hypothesis that mutations in AL LC
alter the folding/unfolding pathway rather than destabilize
global LC structure. Twomutations (T14A and Q44H) lie at or
near the interface between the VL and CL domains, and five
mutations lie at the LC dimer interface, suggesting that they
may alter interdomain contacts. A future full analysis of all nine
LC sequences will allow us to assess whether these structural
features are unique to -AL-1 or whether they are common to
amyloid-forming LC proteins.
The significance of full-length LC for amyloid formation was
only recently addressed (27–30). These studies find that inter-
actions between the constant and variable domain of LC
alter the unfolding/folding pathways and that the unfolding
of native state LC is a complex, often irreversible, process.
The independent unfolding of the two protein domains fails
to explain the observed unfolding dynamics (28, 29, 63). Fur-
thermore, thermodynamic instability is not sufficient for
amyloid formation, suggesting the importance of kinetic fac-
tors (27, 30). All studies suggest that the enhanced aggrega-
tion of the full-length protein results not only from the com-
bined aggregating propensities of its variable and constant
domain but also from the intramolecular interactions between
these regions.
FIGURE8.DenaturingSDS-PAGE (DTT,heating to95 °C)of timepoints fromaggregationassayover21days in thepresenceandabsenceof equimolar
EGCG. Aggregates of all LC samples were resistant to denaturation only when formed in the presence of EGCG.
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Our study supports the view that full-length LC differ not
only in stability but also in reversibility of unfolding, suggesting
different unfolding/folding pathways. Whereas the denatur-
ation of most LC was reversible, all -MM LC denatured irre-
versibly after heating. We found that - and -isotype LC had
different stabilities in thermal denaturation, with an averageTm
of 53  5 and 59  2 °C, respectively, which corresponds to
previously published data (28, 30, 44, 64). We did not find
strong systematic differences in stability between AL- and
MM-LC. MM-LC had, on average, slightly higher unfolding
energies than AL-LC.We also observed slightly higher melting
points of -MM-LC compared with -AL-LC from thermal
denaturation, which would correspond to the results from iso-
lated VL domains (18). In general, our data support the model
that amyloid propensity is unique to each LC and does not
correlate strongly with thermodynamic stability.
Our study also supports data from isolated VL domains,
which suggest that disruption of intermolecular disulfide bonds
in LC dimers is a prerequisite of amyloid formation (61, 65).
This model is also supported by data from a recent drug screen
(66). We found that 50% of LC in urine existed as disulfide-
cross-linked dimers, and all LC existed as di- or multimers
under native conditions. Efficient amyloid formation under our
experimental conditions required the reduction of intermo-
lecular disulfide bonds. Although disulfide bonds were not
reduced in other aggregation studies of LC, these studies
employed temperatures near themelting point, low pH, and/or
very long incubation times to achieve amyloid formation (27,
30). These results suggest that the stability of folded light chains
needs to be compromised for amyloid formation. Although
analysis of LC from serum by immunoaffinity LC-MS/MS (67)
did not resolve to what degree disulfide-linked dimers are pres-
ent in the serum of patients, our data suggest that a reducing
milieu may initiate amyloid formation in vivo. Specifically,
aggregation was initiated by the reduction of interchain and
intermolecular disulfide bonds. In contrast, intradomain disul-
fide bond were only cleaved under denaturing conditions but
stayed intact under native conditions (43). We found that LC
were present in oligomeric form in the urine samples. After
reduction of intermolecular disulfide bonds, LC ran as mono-
mers in native PAGE, suggesting that disulfide bonds stabilized
LC oligomers.
Both theVL andCLdomains of LCdisplay complex unfolding
mechanisms (68, 69). Our data suggest that reduction of inter-
molecular disulfide bonds did not alter LC domain structure.
However, it made protein surfaces accessible that would other-
wise be obstructed in the di- or oligomer. Notably, the amy-
loidogenic regions of the -AL-1 LC map to a single defined
region on the surface of the VL domain (Fig. 4A). We hypothe-
size that monomerization enabled LC to enter a partial unfold-
ing route that allows amyloid formation. This model would
explain the two-phase aggregation kinetics with a first fast
DTT-dependent oligomeric phase and a second phase where
cross--sheet structures are formed, which were inhibited by
EGCG.
VL domains of light chains form amyloid fibrils under acidic
and neutral conditions (18, 70). Meshlike structures were
observed after prolonged incubation of recombinant full-
length LC at neutral pH under permanent shaking (30). We
found that patient-derived LC fromAL patients formed similar
fibril cluster structures after 3 weeks of constant agitation (Fig.
4C and supplemental Fig. 2). These aggregates bound the amy-
loidophilic dyes ThT and Congo red and showed Congo red
birefringence, suggesting that they contained cross--sheet
amyloid structures.
Aggregation studies of recombinant VL and LC find sigmoi-
dal aggregation kinetics typical of amyloid formation. Our
study found that native reducing conditions rapidly induce
amyloid formation of authentic LC at physiological pH, salt,
and temperature. Kinetics could be described by a common
two-phase aggregation mechanism. The first phase was inde-
pendent of the LC concentration and varied in relative ThT
fluorescence amplitude. The second phase displayed sigmoid
kinetics. Two-phase aggregation kinetics have been observed in
FIGURE 9. Ultracentrifugation experiment at the 21-day aggregation
time point with and without EGCG. LC proteins became insoluble both in
the presence and in the absence of EGCG. Gels show equivalent amounts of
total protein before ultracentrifugation (top), protein in the soluble fractions
(middle), and protein in the insoluble fractions (bottom).
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A aggregation, where oligomers formed in the first aggrega-
tion phase (71, 72). Non-amyloid aggregation processes with
oligomer formation also present similar kinetics (73).
The first phase of LC aggregation kinetics depended on the
DTT concentration but not on LC concentration, suggesting
that reduction of disulfide bonds is the rate-limiting process
resulting in the formation of LC oligomers. The second aggre-
gation phase was concentration-dependent for most light
chains. However, analysis of the reaction order in a double log-
arithmic plot as a function of LC concentration suggests that
conformational change rather than aggregate assembly or
propagation may be limiting amyloid formation at low LC
concentrations.
At high protein concentrations, aggregation of light chains
from AL patients switched from kinetics that were dominated
by structural conversion to kinetics that are compatible with a
nucleated polymerization mechanism. These data suggest that
AL and MM LC may differ in the kinetics of early conforma-
tional change, which makes the protein competent for amyloid
formation. Our data also suggest that molecular AL and MM
pathologies could exist on a continuum and that additional fac-
tors, such as protein homeostasis, may determine the ultimate
fate of LC in vivo (74).
Although our use of authentic LC from urine avoided poten-
tial bias from lack of posttranslational modifications, it may
have introduced a degree of sampling bias. We found that the
albumin in the urine of AL patients with albuminuria tightly
bound to LC and co-eluted with the light chains in size exclu-
sion chromatography (data not shown). It was reported that
albumin can bind proteins covalently via disulfide bond forma-
tion (75, 76), but our biochemical analysis under non-reducing
conditions indicated a non-covalent bindingmode between the
two proteins (Fig. 1B). The strong interaction between albumin
and LC made it impossible to purify LC from the urine of
patients with albuminuria under native conditions. We there-
fore excluded urine samples with high albumin content from
the analysis.
We performed patient selection, sample purification, and
biophysical studies blind to the detailed clinical diagnosis. After
unblinding the patient samples, we found that our selection
criteria (high LC, low albumin) directed AL patient selection
toward AL deposits in soft tissue and gastrointestinal tract
(Table 1). As a consequence, the underlying plasma cell clone of
all of theseAL patients had expanded to symptomaticMMwith
bone lesions. The fact that our experimental approach selected
for AL patients with a “weak” amyloid deposition phenotype
may account for the modest differences in aggregation kinetics
between AL and MM patient samples. It is reasonable to
assume that LC proteins from AL patients with strong heart or
kidney pathology would display a stronger difference in aggrega-
tion kinetics fromMMLC, as hadbeenobserved in previous stud-
ies (27).
Since its discovery as an anti-amyloid agent, the mechanism
of EGCG has been studied in a number of proteins. EGCG pre-
vented fibril formation in A and -Syn aggregation (31, 32,
77), delayed aggregation kinetics (31, 32, 55, 78–81), and redi-
rected misfolded proteins into SDS-stable aggregates (31, 32,
55, 56, 79). Treatment with EGCG disaggregated preformed
amyloid fibrils by remodeling them into large amorphous
aggregates (31, 56, 77) and reduced amyloid seeding compe-
tence (31, 32, 56, 82, 83).
We have studied the effect of EGCG on nine authentic
full-length LC proteins and found that EGCG had a generic,
sequence-independent effect on light chain aggregation. It pre-
vented the second aggregation phase and induced the forma-
tion of SDS-stable aggregates. These observations are similar to
those in A and -Syn aggregation, suggesting a similar mech-
anism, inwhich EGCGpreferentially interactswith aggregation
intermediates of LC and inactivates them via off-pathway
aggregate formation. This is seemingly in contrast to recent
data finding that EGCG binds to the VL domain of LC with 1:1
stoichiometry and a dissociation constant of75 M (80).
However, binding studies on A revealed that EGCG can
interact both with the monomeric peptide (84, 85) and with
amyloid fibrils (56, 82). When systematically reviewing EGCG
mechanisms in various proteins, we found that EGCG binding
to aggregation intermediates may inhibit amyloid formation
very effectively in cases where these species are rate-limiting to
amyloid formation (57). In other cases, amyloid formation is
dominated by a structural transition or dissociation of the
native protein. Here, EGCG may bind to native proteins and
have less of an effect on kinetics butmay nevertheless divert the
protein into stable non-amyloid aggregates (57).
We find that EGCG effectively inhibits amyloid formation of
a variety of light chains in vitro. This suggests that treatment
with anti-amyloid drugs that either stabilize the native LC
dimer or inhibit amyloid formationmay be a promising supple-
mental therapeutic strategy to ameliorate the amyloid pathol-
ogy in AL patients. It would therefore be valuable to assess the
potential of drugs, such as EGCG, methylene blue, and Orcein/
O4, which have proven effective in inhibiting amyloid forma-
tion in other disease-related proteins, for the treatment of AL
amyloidosis (32, 66, 86).
Experimental Procedures
Diagnosis andPatient Selection forThis Study—Patientswere
diagnosed for monoclonal gammopathy by FLC from serum
and immunofixation electrophoresis from serum as well as
from urine (87). The diagnosis of AL amyloidosis was estab-
lished via Congo red staining of fat aspirates and/or tissue biop-
sies (6) at the Amyloidosis Center Heidelberg according to
established clinical protocols and in compliance with the ethi-
cal guidelines for treatment and patient consent. Patients were
selectedwho presentedwith265mg/24 h clonal light chain in
urine but without significant albuminuria (	6% albumin). 24-h
urine samples were collected, and aliquots of 4  15 ml were
frozen afterward at 20 °C for storage in the Heidelberg
Amyloidosis Center biobank. Nine immunoglobulin light
chains were purified from patient urine and subsequently
analyzed: 2 -AL, 2 -AL, 2 -MM, and 3 -MM
(Table 1). The deposition patterns in the AL patients were
blinded until after all experimental data were acquired.
Light Chain Protein Purification from Human Urine—Im-
munoglobulin light chainswere isolated frompatients suffering
from AL or MM as follows. Particulate matter was removed
from 20–40 ml of patient urine by centrifugation for 15 min at
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4,500 g at 4 °C, followed by sequential filtration through first
a 5-m and second a 0.22-m syringe membrane filter (Milli-
pore). Afterward, the protein was concentrated in ultrafiltra-
tion units (Amicon Ultra 15) to 0.5 ml and buffer-exchanged in
the same by six sequential dilution and reconcentration steps in
50 mM sodium phosphate (NaP) buffer, pH 7.2 (6 15 ml).
Total protein concentrationswere determined via BCAassay
(Pierce). The albumin content was estimated densitometrically
from silver-stained SDS-PAGE versus an HSA standard. Sam-
ples were adjusted to final LC concentrations of 1 mM, flash-
frozen, and stored at80 °C.
LC-MS/MS-based Sequencing—Lyophilized -AL-1 sample
(5 g) was reconstituted with 20 l of ultrapure water. Gel
bands from reducing SDS-PAGE were excised, destained,
reduced, and alkylated as described previously (49). The protein
was digested in-gel at 37 °C overnight with 0.025 g/l trypsin
(Promega) or chymotrypsin (bovine; Promega) and for 3 h at
room temperature with 0.025 g/l GluC (Staphylococcus
aureus, Roche Applied Science) in 20mMTris, pH 8.2, 0.0002%
Zwittergent 3-16. Peptide extraction was performed in two
steps with 25 l of 2% trifluoroacetic acid and 50 l of acetoni-
trile. Samples were lyophilized and stored at80 °C beforeMS
analysis.
Nano-LC-electrospray ionization-MS/MS measurements
were performed as described previously (49) with an Orbitrap
Elite detector and the following LC gradient of solvent B: 5 to
45% in 39 min, 45 to 90% in 2 min, 90% for 5 min, 90 to 5% in 2
min. The mass spectrometer performed a full scan MS scan
from 340–1,500m/z, with a resolution of 140,000, followed by
MS/MS scans at a resolution of 17,500. The Top20 [M 2H]
2, [M 3H] 3, and [M 4H] 4 ions were analyzed in
a 1.5m/z isolation window.
MS data were processed in PEAKS Studio software (Bioin-
formatics Solutions, Waterloo, Canada). For peptide mapping,
a homemade IMGT-derived LC sequence database and the
Uniprot human protein database were combined. The IMGT-
derived database contained VL-JL-CL transition peptide
sequences, and complete VL and CL domain sequences. Data-
base searches and de novo sequencing were performed assum-
ing cysteine carbamidomethylation as a fixedmodification, and
methionine oxidations and asparagine/glutamine deamination
as variable modifications. Additionally, the PEAKS PTM and
the SPIDER search algorithm were used to detect PTMs and
mutations. A precursor mass tolerance of 4.5 ppm and a frag-
ment tolerance of 0.02 Da (49) were selected.
Relevant identified peptide sequences were determined
by base peak interrogation as described previously (49) and
aligned to the IMGT numbering system (16, 17, 45) with the
IMGT/DomainGapAlign tool (88). Missing sequence patches
were identified via inverse interrogation of the PEAKS results
and LC-MS/MS data. The sequence representation shown here
was created using the IMGT/Collier de Perles tool (89, 90).
Amino acids are numbered according to the IMGT numbering
system. Amyloidogenicity of LC sequence was predicted using
the WALTZ online tool, as described (50).
Gel Electrophoresis, Western Blotting Analysis, SDS Stability
Assays, andMolecularWeight Determination—For SDS-PAGE
and blue native PAGE, NuPAGE and NativePAGE precast gel
systems (Invitrogen) were used with precast gradient gels
(3–12% and 4–12%, respectively). For SDS-PAGE, samples
were diluted in LDS sample buffer (Invitrogen) either reduced
with DTT (187.5 mM) and heated for 10 min to 95 °C (denatur-
ing conditions) or directly applied to the gel (semidenaturing).
Gel bands were visualized either by Coomassie staining (EZ
blue) or silver staining (ProteoSilver kit, both from Sigma-Al-
drich) according to the manufacturer’s protocols with minor
changes. In short, the volumes of all kit components were
reduced by a factor of 4, whereas the volumes of fixing solution,
ethanol, and water washes were reduced by a factor of 2. The
gelswere stained in single-use plastic dishes, and the incubation
with the silver solutionwas elongated to 15min, following three
short consecutive rinsing steps with ultrapure water.
For Western blotting analysis, proteins were transferred to
nitrocellulose membranes. Membranes were blocked for 30
min in 3%milk in PBS and then were either immunostained for
-isotype LC and HSA or -isotype LC and HSA in parallel. As
primary antibodies, we used polyclonal goat anti-human Ig 
chain, polyclonal goat anti-human Ig chain (both 1:2,000;Mil-
lipore, AP506 and AP502), and polyclonal rabbit anti-human
HSA (1:2,000; Thermo, R0101-1D). As secondary antibodies
IRDye 800CW donkey anti-goat IgG and LI-COR IRDye
680RD donkey anti-rabbit IgG were used (both 1:15,000; LI-
COR, 926-32214 and 926-68073). All antibodies were diluted in
3% milk in PBS. Secondary antibodies were detected in a fluo-
rescent detection system (LI-COR) at 800-nm (LC) or 700-nm
wavelength (HSA). We determined the apparent molecular
weight of the light chains comparedwith a proteinmarker (Pre-
cision Dual Plus, Bio-Rad) from three independent SDS-PAGE
samples.
CD Spectroscopy, Thermal and Chemical Denaturation—CD
spectroscopy was performed in a JASCO J-810 CD spectrome-
ter. CD spectra were accumulated between 265 and 190 nm
with bandwidth 1 nm, response time 8 s, standard sensitivity,
data pitch 0.5 nm, scanning speed 50 nm/min, 0.1-cm cell
length at 20 °C, and 3 accumulations at a concentration of
10–20 M LC in NaP buffer. Thermal de- and renaturations
were performed in triplicate at a temperature slope of 0.5 °C/
min. Spectra before and after denaturation and after renatur-
ation were acquired to test for refolding of the light chains. For
thermal denaturation under reducing conditions, LC (200 M)
was reduced with DTT (10 mM) for 2 h at room temperature
either in NaP buffer or in 2 M GdnHCl. LC samples were rena-
tured by dilution to 10 M in NaP.
GdnHCl denaturationwas performed in biological triplicates
by incubating the samples overnight at the respective concen-
trations of GdnHCl in NaP buffer before measurement. For
renaturation samples, the protein was unfolded overnight at
100M LC and 6 MGdnHCl, diluted to 10M LC at the desired
GdnHCl concentration, and incubated for at least 8 h. ForGdn-
HCl denaturation, three CD spectra with three accumulations
were measured between 213 and 211 nm using the spectrom-
eter’s interval measurement mode with bandwidth 1 nm,
response time 16 s, standard sensitivity, data pitch 0.1 nm, scan-
ning speed 20 nm/min, and 0.1-cm cell length, at a concentra-
tion of 10 M at 20 °C. Protein unfolding curves were deter-
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mined at 211 nm. Spectra before and after denaturation and
after renaturation were acquired as described above.
Tryptophan Fluorescence Spectroscopy, Guanidine Dena-
turation—We incubated LC samples overnight in biological
triplicates, andTrp fluorescencewas recorded between 300 and
470 nm in a spectrofluorimeter (Photon Technology Interna-
tional) at room temperature at 0.5 M LC in NaP, excitation at
280 nm. Samples for GdnHCl denaturation were prepared as
described for CD but in disposable borosilicate glass culture
tubes (10 75mm) (Fisher) to avoid the leaching of fluorescent
molecules from plastic tubes into the sample.
To calculate the degree of unfolding, we determined the ra-
tio between fluorescence intensities of the emission maxi-
mum before denaturation (e.g. 339 nm) and after denaturation
(e.g. 351 nm). Different samples exhibited different peak
shifts, which are summarized in Table 2.
Aggregation Assays—Short term aggregation assays were
performed with the following parameters: 5–100 M LC, NaP
buffer (pH 7.2), 150 mM sodium chloride, 100 mM DTT, 20 M
ThT, 0.05% sodium azide, with or without EGCG (equimolar,
5 equimolar; Taiyo) in a 100-l volume in non-binding sur-
face 96-well plates, (Corning, catalog no. 3991). For measure-
ments, we used a Tecan Infinite F200 filter based plate reader,
436/10-nmexcitation band pass filter, and 482/25-nmemission
filter. Measurements were performed at 37 °C after 5 s of linear
shaking with 2.5-mm amplitude in 15-min cycles. For turbidity
measurements, absorption was measured at 560 nm. In
concentration-dependent aggregation assays, we ran back-
ground traces containing the respective albumin concentration
and subtracted the albumin signal before analyzing the data
further.
Long term aggregation assays were performed in 200-l
8-tube PCR strips (Simport Scientific, Saint-Mathieu-de-Be-
loei, Canada) with 20 M LC, 25 mM sodium phosphate (NaP2,
pH 7.2), 120 mM sodium chloride, 8 mM DTT, 16 M ThT,
0.05% sodium azide, and 50-l assay volume. Quadruplicates
were incubated with and without 40 M EGCG for different
time periods up to 21 days under permanent shaking with 200
rpm at 37 °C in an incubator shaker (New Brunswick). Samples
were stored at80 °C at each time point, afterward pipetted in
non-binding surface 348-well plates (Corning, catalog no.
3544). Absorption and/or ThT fluorescence were measured as
described above, including prior shaking. Samples were recov-
ered from 348-well plates for further biochemical analysis. For
EGCG stock solutions, EGCG was dissolved and diluted in
ultrapure water directly before use.
Ultracentrifugation Assays—Ultracentrifugation assays were
performed in a Beckman TL-100 ultracentrifuge, with a TLA-
100 fixed angle rotor in thick walled polycarbonate 200-l
tubes (Beckman Coulter) at 75,000 rpm (189,000–245,000 g)
and 4 °C. The pellets were washed with 200 l of NaP buffer,
again centrifuged for 30 min, and resuspended in SDS-PAGE
LDS sample buffer, 187.5 mM DTT, and boiled for 5 min and
analyzed by SDS-PAGE.
Atomic ForceMicroscopy Imaging—ForAFMmeasurements,
10l of 5M sample was applied to grade V-1Mica (catalog no.
01792-AB, Structure Probe, Inc.), followed by six wash steps
with 15 l of ultrapure water. Samples were dried overnight,
and AFM images were acquired on a Veeco Dimension 3100
machine with Bruker FESP tips. Scans were accumulated in
tapping mode with 512 points/line for 10  10- or 3  3-m
scan range, with a scan rate of 0.6 Hz.
Congo Red Staining and Imaging—Congo red (50 M) was
added to -AL-1 LC (20 M) that had been aggregated for 1
week under standard conditions. The aggregate solution was
pipetted on a coverslip and imaged by fluorescencemicroscopy
and by birefringence in a Zeiss Axio imager at 5 magnifica-
tion. Fluorescence was detected at 546 nm excitation and 575–
640 nm emission. Birefringence was measured under white
light using two polarizers angled at 90°.
Evaluation of Unfolding Data—To determine unfolding
energies for light chain proteins by CD and/or fluorescence
spectroscopy, different properties had to be evaluated for dif-
ferent samples due to structural characteristics: (a) the elliptic-
ity at 211 nm for the fluorescence intensity for samples -AL-1,
-MM-2, and -MM-2; (b) the fluorescence intensity at 350 nm
for the -AL-2; and (c) the ratio between fluorescence intensi-
ties at the lowest and the highest wavelength at the peak maxi-
mum observed for the other -LC samples. Unfolding curves
were calculated from raw data as a function of the GdnHCl
concentration by first correcting for pre- and post-transition
baseline. Second, we assumed a two-state transition for the
unfolding, an equilibrium state at each data point, and a com-
pletely folded and unfolded state at the beginning and end
GdnHCl concentration, respectively. For each sample, the tran-
sition unfolding equilibrium constants K and ln K were deter-
mined as a function of the GdnHCl concentration. The Gibbs
free energy (
G0) was determined via linear regression from
Equation 1 (91).
ln Km cdenaturant	 
G0RT (Eq. 1)
Fitting of ThT Aggregation Curves—Concentration-depen-
dent aggregation data were fitted with a two-phase Boltzmann
growth function with a linear correction term (Equation 2).
Time constants of Boltzmann growth phases were plotted dou-
ble logarithmically as functions of initial LC concentration and
data points fitted with linear regression.
y  A0 	
A1 
 A0
1 	 expt1x/dx1
	
A2A1
1	 expt2x/dx2
	m x (Eq. 2)
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Supplementary Figure 1 
Reversibility of GdnHCl denaturation. CD spectra of LC samples under native conditions (folded), in 6M 
GdnHCl (unfolded) and LC diluted from 6M GdnHCl to 60 mM GdnHCl (refolded). 
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Supplementary Figure 2 
AFM imaging of long-term aggregation assay with permanent shaking for 21 days under neutral conditions in 
absence or presence of equimolar EGCG (Compare to Fig. 4, 5, 8, and 9) or for 24 days under acidic conditions 
(25 µM LC, 50 mM Glycine / HCl pH 2.8, 150 mM NaCl, 0.05% NaN3, 100 mM DTT, 20 µM ThT). 
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Supplementary Figure 3 
A) Supplementary kinetics for Fig. 6B - ThT aggregation kinetics at different LC protein concentrations. 
Samples show biphasic aggregation kinetics. B) First phase time constants for biphasic aggregation fits. 
Concentrations 11 µM and 5µM of λ-AL-1LC were fitted without a first aggregation phase. C) κ-AL-1 LC 
aggregation kinetics in presence of 0.2, 1, and 2 µM HSA. ThT fluorescence from HSA samples without LC was 
subtracted to generate LC ThT fluorescence kinetics. The presence of HSA slightly delayed the second 
aggregation phase of LC kinetics, but had no effect on the first phase. All plots represent averages of triplicate 
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samples. D) DTT-dependent aggregation kinetics – Aggregation kinetics performed under standard conditions, at 
DTT concentrations of 10, 50, 100, and 200 mM. The first aggregation phase is accelerated by increasing DTT 
concentrations. All plots represent averages of triplicate samples. 
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Supplementary Figure 4 
Supplementary kinetics for Fig. 7 – A) ThT kinetics in absence (0x) of EGCG, with equimolar EGCG (1x) and 
five-fold excess EGCG (5x) in relation to the LC concentration. EGCG prevented formation of ThT positive 
species in the second aggregation phase; full kinetics & zoom of the first 2.5 days of aggregation. All plots 
represent averages of triplicate samples. B) κ-AL-1 LC (25 µM, NaP buffer pH 7.4) aggregation kinetics in 
absence (0x) of EGCG, with equimolar EGCG (1x) added at the beginning of the assay or after 4 h incubation. 
EGCG prevented formation of ThT positive species in the second aggregation phase. 
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